JNK inhibitor and ferroptosis modulator as possible therapeutic modalities in Alzheimer disease (AD).
Alzheimer Disease
/ drug therapy
Ferroptosis
/ drug effects
Animals
Mice
Disease Models, Animal
Ciclopirox
/ pharmacology
Anthracenes
/ pharmacology
Male
Aluminum Chloride
Hippocampus
/ metabolism
Neuroprotective Agents
/ pharmacology
Amyloid beta-Peptides
/ metabolism
JNK Mitogen-Activated Protein Kinases
/ metabolism
Iron
/ metabolism
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
07 10 2024
07 10 2024
Historique:
received:
12
01
2024
accepted:
19
09
2024
medline:
8
10
2024
pubmed:
8
10
2024
entrez:
7
10
2024
Statut:
epublish
Résumé
Alzheimer disease (AD) is among the most prevalent neurodegenerative diseases globally, marked by cognitive and behavioral disruptions. Ferroptosis is a form of controlled cell death characterized by intracellular iron accumulation associated with lipid peroxide formation, which subsequently promotes AD initiation and progression. We hypothesized that targeting the ferroptosis pathway may help in AD management. Therefore, our study aimed to evaluate the potential neuroprotective effect of the antifungal Ciclopirox olamine (CPX-O) that acts through iron chelation. We employed CPX-O separately or in combination with the JNK inhibitor (SP600125) in a mice model of AlCl
Identifiants
pubmed: 39375359
doi: 10.1038/s41598-024-73596-1
pii: 10.1038/s41598-024-73596-1
doi:
Substances chimiques
Ciclopirox
19W019ZDRJ
Anthracenes
0
pyrazolanthrone
1TW30Y2766
Aluminum Chloride
3CYT62D3GA
Neuroprotective Agents
0
Amyloid beta-Peptides
0
JNK Mitogen-Activated Protein Kinases
EC 2.7.11.24
Iron
E1UOL152H7
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
23293Informations de copyright
© 2024. The Author(s).
Références
Zhang, G. et al. The potential role of ferroptosis in Alzheimer’s disease. J. Alzheimers Dis. 80, 907–925 (2021).
pubmed: 33646161
doi: 10.3233/JAD-201369
Zhang, X. X. et al. The epidemiology of Alzheimer’s Disease Modifiable Risk factors and Prevention. J. Prev. Alzheimer’s Disease. 8, 313–321. https://doi.org/10.14283/jpad.2021.15 (2021).
doi: 10.14283/jpad.2021.15
Shunan, D., Yu, M., Guan, H. & Zhou, Y. Neuroprotective effect of Betalain against AlCl3-induced Alzheimer’s disease in Sprague Dawley rats via putative modulation of oxidative stress and nuclear factor kappa B (NF-κB) signaling pathway. Biomed. Pharmacother. 137, 111369 (2021).
pubmed: 33582452
doi: 10.1016/j.biopha.2021.111369
Adlimoghaddam, A., Neuendorff, M., Roy, B. & Albensi, B. C. A review of clinical treatment considerations of donepezil in severe Alzheimer’s disease. CNS Neurosci. Ther. 24, 876–888 (2018).
pubmed: 30058285
pmcid: 6489741
doi: 10.1111/cns.13035
Nafea, M., Elharoun, M., Abd-Alhaseeb, M. M. & Helmy, M. W. Leflunomide abrogates neuroinflammatory changes in a rat model of Alzheimer’s disease: the role of TNF-α/NF-κB/IL-1β axis inhibition. Naunyn Schmiedebergs Arch. Pharmacol. 396, 485–498. https://doi.org/10.1007/s00210-022-02322-3 (2023).
doi: 10.1007/s00210-022-02322-3
pubmed: 36385687
Van Bergen, J. M. et al. Simultaneous quantitative susceptibility mapping and Flutemetamol-PET suggests local correlation of iron and β-amyloid as an indicator of cognitive performance at high age. Neuroimage. 174, 308–316 (2018).
pubmed: 29548847
doi: 10.1016/j.neuroimage.2018.03.021
Zhao, D. et al. Mechanisms of ferroptosis in Alzheimer’s disease and therapeutic effects of natural plant products: a review. Biomed. Pharmacother. 164, 114312 (2023).
pubmed: 37210894
doi: 10.1016/j.biopha.2023.114312
Dixon, S. J. et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 149, 1060–1072 (2012).
pubmed: 22632970
pmcid: 3367386
doi: 10.1016/j.cell.2012.03.042
Stockwell, B. R. et al. Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease. Cell. 171, 273–285 (2017).
pubmed: 28985560
pmcid: 5685180
doi: 10.1016/j.cell.2017.09.021
Liu, M., Zhu, W. & Pei D.-s. System Xc–: a key regulatory target of ferroptosis in cancer. Investig. New Drugs. 39, 1123–1131 (2021).
doi: 10.1007/s10637-021-01070-0
Song, X. et al. AMPK-mediated BECN1 phosphorylation promotes ferroptosis by directly blocking system Xc–activity. Curr. Biol. 28, 2388–2399 (2018).
pubmed: 30057310
pmcid: 6081251
doi: 10.1016/j.cub.2018.05.094
Reichert, C. O. et al. Ferroptosis mechanisms involved in neurodegenerative diseases. Int. J. Mol. Sci. 21, 8765 (2020).
pubmed: 33233496
pmcid: 7699575
doi: 10.3390/ijms21228765
Li, S. & Huang, Y. Ferroptosis: an iron-dependent cell death form linking metabolism, diseases, immune cell and targeted therapy. Clin. Transl. Oncol. 24, 1–12. https://doi.org/10.1007/s12094-021-02669-8 (2022).
doi: 10.1007/s12094-021-02669-8
pubmed: 34160772
Cao, J. Y. & Dixon, S. J. Mechanisms of ferroptosis. Cell. Mol. Life Sci. 73, 2195–2209. https://doi.org/10.1007/s00018-016-2194-1 (2016).
doi: 10.1007/s00018-016-2194-1
pubmed: 27048822
pmcid: 4887533
Shin, D., Kim, E. H., Lee, J. & Roh, J. L. Nrf2 inhibition reverses resistance to GPX4 inhibitor-induced ferroptosis in head and neck cancer. Free Radic. Biol. Med. 129, 454–462 (2018).
pubmed: 30339884
doi: 10.1016/j.freeradbiomed.2018.10.426
Raffaele, I., Silvestro, S. & Mazzon, E. MicroRNAs and MAPKs: evidence of these molecular interactions in Alzheimer’s Disease. Int. J. Mol. Sci. 24, 4736 (2023).
pubmed: 36902178
pmcid: 10003111
doi: 10.3390/ijms24054736
Wu, C. et al. Induction of ferroptosis and mitochondrial dysfunction by oxidative stress in PC12 cells. Sci. Rep. 8, 1–11 (2018).
Kim, E. K. & Choi, E. J. Pathological roles of MAPK signaling pathways in human diseases. Biochim. Biophys. Acta. 1802, 396–405. https://doi.org/10.1016/j.bbadis.2009.12.009 (2010).
doi: 10.1016/j.bbadis.2009.12.009
pubmed: 20079433
Priori, E. C. et al. JNK Activation Correlates with Cognitive Impairment and Alteration of the Post-Synaptic Element in the 5xFAD AD Mouse Model. Cells 12, doi: (2023). https://doi.org/10.3390/cells12060904
Everett, J. et al. Evidence of redox-active iron formation following aggregation of ferrihydrite and the Alzheimer’s disease peptide β-amyloid. Inorg. Chem. 53, 2803–2809 (2014).
pubmed: 24559299
doi: 10.1021/ic402406g
Sonthalia, S., Agrawal, M. & Sehgal, V. Topical ciclopirox olamine 1%: revisiting a unique antifungal. Indian Dermatology Online J. 10, 481 (2019).
doi: 10.4103/idoj.IDOJ_29_19
Subissi, A., Monti, D., Togni, G. & Mailland, F. Ciclopirox: recent nonclinical and clinical data relevant to its use as a topical antimycotic agent. Drugs. 70, 2133–2152 (2010).
pubmed: 20964457
doi: 10.2165/11538110-000000000-00000
Krasovskiĭ, G. N., Vasukovich, L. Y. & Chariev, O. G. Experimental study of biological effects of leads and aluminum following oral administration. Environ. Health Perspect. 30, 47–51. https://doi.org/10.1289/ehp.30-1637724 (1979).
doi: 10.1289/ehp.30-1637724
pubmed: 446457
pmcid: 1637724
Ahmed, H. H., Salem, A. Z. M., Sabry, G. M., Husein, A. A. & Kotob S. E. (2015).
Mohamed, A. B., Mohamed, A. Z. & Aly, S. Effect of Thymoquinone against Aluminum Chloride-Induced Alzheimer-Like Model in rats: a neurophysiological and behavioral study. Med. J. Cairo Univ. 88, 355–365 (2020).
doi: 10.21608/mjcu.2020.93997
Nair, A. B. & Jacob, S. A simple practice guide for dose conversion between animals and human. J. Basic. Clin. Pharm. 7, 27–31. https://doi.org/10.4103/0976-0105.177703 (2016).
doi: 10.4103/0976-0105.177703
pubmed: 27057123
pmcid: 4804402
Eberhard, Y. et al. Chelation of intracellular iron with the antifungal agent ciclopirox olamine induces cell death in leukemia and myeloma cells. Blood J. Am. Soc. Hematol. 114, 3064–3073 (2009).
Rahman, M., Zhang, Z., Mody, A. A., Su, D. M. & Das, H. K. Intraperitoneal injection of JNK-specific inhibitor SP600125 inhibits the expression of presenilin-1 and notch signaling in mouse brain without induction of apoptosis. Brain Res. 1448, 117–128 (2012).
pubmed: 22353755
pmcid: 3310381
doi: 10.1016/j.brainres.2012.01.066
Wang, S. et al. Expression and functional profiling of neprilysin, insulin-degrading enzyme, and endothelin‐converting enzyme in prospectively studied elderly and Alzheimer’s brain. J. Neurochem. 115, 47–57 (2010).
pubmed: 20663017
pmcid: 2939954
doi: 10.1111/j.1471-4159.2010.06899.x
Gargiulo, S. et al. Mice Anesthesia, Analgesia, and Care, Part I: anesthetic considerations in Preclinical Research. ILAR J. 53, E55–E69. https://doi.org/10.1093/ilar.53.1.55 (2012).
doi: 10.1093/ilar.53.1.55
pubmed: 23382271
Suvarna, K. S., Layton, C. & Bancroft, J. D. Bancroft’s theory and practice of histological techniques (eighth edn, (Elsevier health sciences, 2018).
Khalil, R. et al. Vildagliptin, a DPP-4 inhibitor, attenuates carbon tetrachloride-induced liver fibrosis by targeting ERK1/2, p38α, and NF-κB signaling. Toxicol. Appl. Pharmcol. 407, 115246 (2020).
doi: 10.1016/j.taap.2020.115246
Chen, L. et al. Autophagy inhibition contributes to the synergistic interaction between EGCG and doxorubicin to kill the hepatoma Hep3B cells. PloS One. 9, e85771 (2014).
pubmed: 24465696
pmcid: 3897495
doi: 10.1371/journal.pone.0085771
Zaher, M. F., Bendary, M. A., El-Aziz, A. & Ali, A. S. G. S. Potential protective role of thymoquinone on experimentally-induced Alzheimer rats Vol. 6 (King Abdulaziz University, Jeddah, Saudi Arabia, 2020).
Sharma, N., Deshmukh, R. & Bedi, K. L. SP600125, a competitive inhibitor of JNK attenuates streptozotocin induced neurocognitive deficit and oxidative stress in rats. Pharmacol. Biochem. Behav. 96, 386–394. https://doi.org/10.1016/j.pbb.2010.06.010 (2010).
doi: 10.1016/j.pbb.2010.06.010
pubmed: 20600246
Zhou, Q. et al. Inhibition of c-Jun N-terminal kinase activation reverses Alzheimer disease phenotypes in APPswe/PS1dE9 mice. Ann. Neurol. 77, 637–654. https://doi.org/10.1002/ana.24361 (2015).
doi: 10.1002/ana.24361
pubmed: 25611954
Wu, C. et al. Induction of ferroptosis and mitochondrial dysfunction by oxidative stress in PC12 cells. Sci. Rep. 8, 574 (2018).
pubmed: 29330409
pmcid: 5766540
doi: 10.1038/s41598-017-18935-1
Cho, H. & Hah, J. M. A perspective on the development of c-jun N-terminal kinase inhibitors as therapeutics for alzheimer’s disease: investigating structure through docking studies. Biomedicines. 9, 1431 (2021).
pubmed: 34680547
pmcid: 8533360
doi: 10.3390/biomedicines9101431
Hampel, H. et al. The Amyloid-β pathway in Alzheimer’s Disease. Mol. Psychiatry. 26, 5481–5503. https://doi.org/10.1038/s41380-021-01249-0 (2021).
doi: 10.1038/s41380-021-01249-0
pubmed: 34456336
pmcid: 8758495
Elshazly, A. M., Sinanian, M. M., Elimam, D. M. & Zakaria, S. Overview of the Molecular modalities and Signaling pathways intersecting with β-Amyloid and Tau Protein in Alzheimer’s Disease. Neuroglia. 4, 191–208 (2023).
doi: 10.3390/neuroglia4030014
Thinakaran, G. & Koo, E. H. Amyloid precursor protein trafficking, processing, and function. J. Biol. Chem. 283, 29615–29619 (2008).
pubmed: 18650430
pmcid: 2573065
doi: 10.1074/jbc.R800019200
Elreedy, H. A., Elfiky, A. M., Mahmoud, A. A., Ibrahim, K. S. & Ghazy, M. A. Neuroprotective effect of quercetin through targeting key genes involved in aluminum chloride induced Alzheimer’s disease in rats. Egypt. J. Basic. Appl. Sci. 10, 174–184 (2023).
Venugopal, C., Demos, C. M., Jagannatha Rao, K., Pappolla, M. A. & Sambamurti, K. Beta-secretase: structure, function, and evolution. CNS Neurol. Disorders-Drug Targets (Formerly Curr. Drug Targets-CNS Neurol. Disorders). 7, 278–294 (2008).
doi: 10.2174/187152708784936626
Selkoe, D. J. Soluble oligomers of the amyloid β-protein impair synaptic plasticity and behavior. Behav. Brain. Res. 192, 106–113 (2008).
pubmed: 18359102
pmcid: 2601528
doi: 10.1016/j.bbr.2008.02.016
Mondragón-Rodríguez, S., Salgado-Burgos, H. & Peña-Ortega, F. Circuitry and synaptic dysfunction in Alzheimer’s disease: a new tau hypothesis. Neural plasticity (2020). (2020).
Yoon, S. O. et al. JNK3 perpetuates metabolic stress induced by Aβ peptides. Neuron. 75, 824–837 (2012).
pubmed: 22958823
pmcid: 3438522
doi: 10.1016/j.neuron.2012.06.024
Kim, E. K. & Choi, E. J. Pathological roles of MAPK signaling pathways in human diseases. Biochim. et Biophys. Acta (BBA)-Molecular Basis Disease. 1802, 396–405 (2010).
doi: 10.1016/j.bbadis.2009.12.009
Solas, M. et al. JNK activation in Alzheimer’s disease is driven by amyloid β and is Associated with Tau Pathology. ACS Chem. Neurosci. 14, 1524–1534. https://doi.org/10.1021/acschemneuro.3c00093 (2023).
doi: 10.1021/acschemneuro.3c00093
pubmed: 36976903
Zhang, X. et al. Endoplasmic reticulum stress mediates JNK-dependent IRS-1 serine phosphorylation and results in tau hyperphosphorylation in amyloid β oligomer-treated PC12 cells and primary neurons. Gene. 587, 183–193 (2016).
pubmed: 27185631
doi: 10.1016/j.gene.2016.05.018
Ma, H., Dong, Y., Chu, Y., Guo, Y. & Li, L. The mechanisms of ferroptosis and its role in alzheimer’s disease. Front. Mol. Biosci. 9, 965064. https://doi.org/10.3389/fmolb.2022.965064 (2022).
doi: 10.3389/fmolb.2022.965064
pubmed: 36090039
pmcid: 9459389
Manoharan, S. et al. The Role of Reactive Oxygen Species in the Pathogenesis of Alzheimer’s Disease, Parkinson’s Disease, and Huntington’s Disease: A Mini Review. Oxid. Med. Cell. Longev. 2016 (8590578). https://doi.org/10.1155/2016/8590578 (2016).
Xie, Y. et al. Ferroptosis: process and function. Cell. Death Differ. 23, 369–379. https://doi.org/10.1038/cdd.2015.158 (2016).
doi: 10.1038/cdd.2015.158
pubmed: 26794443
pmcid: 5072448
Yang, W. S. et al. Regulation of ferroptotic cancer cell death by GPX4. Cell. 156, 317–331 (2014).
pubmed: 24439385
pmcid: 4076414
doi: 10.1016/j.cell.2013.12.010
Zhou, J. et al. CPX targeting DJ-1 triggers ROS-induced cell death and protective autophagy in colorectal cancer. Theranostics. 9, 5577 (2019).
pubmed: 31534504
pmcid: 6735393
doi: 10.7150/thno.34663
Wan, X. et al. Ciclopirox Olamine induces Proliferation Inhibition and Protective Autophagy in Hepatocellular Carcinoma. Pharmaceuticals (Basel). 16 https://doi.org/10.3390/ph16010113 (2023).
Carmo, P. H. F. et al. Reactive oxygen and nitrogen species are crucial for the antifungal activity of amorolfine and ciclopirox olamine against the dermatophyte Trichophyton Interdigitale. Med. Mycol. 60 https://doi.org/10.1093/mmy/myac058 (2022).
Nakashima, T. et al. Inhibitory or scavenging action of ketoconazole and ciclopiroxolamine against reactive oxygen species released by primed inflammatory cells. Br. J. Dermatol. 156, 720–727. https://doi.org/10.1111/j.1365-2133.2006.07655.x (2007).
doi: 10.1111/j.1365-2133.2006.07655.x
pubmed: 17493071
Regdon, Z. et al. High-content screening identifies inhibitors of oxidative stress‐induced parthanatos: cytoprotective and anti‐inflammatory effects of ciclopirox. Br. J. Pharmacol. 178, 1095–1113 (2021).
pubmed: 33332573
doi: 10.1111/bph.15344
Sharma, N., Deshmukh, R. & Bedi, K. SP600125, a competitive inhibitor of JNK attenuates streptozotocin induced neurocognitive deficit and oxidative stress in rats. Pharmacol. Biochem. Behav. 96, 386–394 (2010).
pubmed: 20600246
doi: 10.1016/j.pbb.2010.06.010
Tamagno, E., Guglielmotto, M., Vasciaveo, V. & Tabaton, M. Oxidative Stress and Beta Amyloid in Alzheimer’s Disease. Which Comes First: The Chicken or the Egg? Antioxid. (Basel). 10. https://doi.org/10.3390/antiox10091479 (2021).
Lian, H. et al. NFκB-activated astroglial release of complement C3 compromises neuronal morphology and function associated with Alzheimer’s disease. Neuron. 85, 101–115 (2015).
pubmed: 25533482
doi: 10.1016/j.neuron.2014.11.018
Von Bernhardi, R., Tichauer, J. E. & Eugenín, J. Aging-dependent changes of microglial cells and their relevance for neurodegenerative disorders. J. Neurochem. 112, 1099–1114 (2010).
doi: 10.1111/j.1471-4159.2009.06537.x
Wilhelmsson, U. et al. Redefining the concept of reactive astrocytes as cells that remain within their unique domains upon reaction to injury. Proc. Natl. Acad. Sci. U S A. 103, 17513–17518. https://doi.org/10.1073/pnas.0602841103 (2006).
doi: 10.1073/pnas.0602841103
pubmed: 17090684
pmcid: 1859960
Kim, K. Y., Shin, K. Y. & Chang, K. A. GFAP as a Potential Biomarker for Alzheimer’s Disease: A Systematic Review and Meta-Analysis. Cells 12, doi: (2023). https://doi.org/10.3390/cells12091309
Simpson, J. E. et al. Astrocyte phenotype in relation to Alzheimer-type pathology in the ageing brain. Neurobiol. Aging. 31, 578–590. https://doi.org/10.1016/j.neurobiolaging.2008.05.015 (2010).
doi: 10.1016/j.neurobiolaging.2008.05.015
pubmed: 18586353
Teunissen, C. E. et al. Blood-based biomarkers for Alzheimer’s disease: towards clinical implementation. Lancet Neurol. 21, 66–77. https://doi.org/10.1016/s1474-4422(21)00361-6 (2022).
doi: 10.1016/s1474-4422(21)00361-6
pubmed: 34838239
Wolfrum, P., Fietz, A., Schnichels, S. & Hurst, J. The function of p53 and its role in Alzheimer’s and Parkinson’s disease compared to age-related macular degeneration. Front. NeuroSci. 16, 1029473 (2022).
pubmed: 36620455
pmcid: 9811148
doi: 10.3389/fnins.2022.1029473
Han, X. J. et al. Amyloid β-42 induces neuronal apoptosis by targeting mitochondria. Mol. Med. Rep. 16, 4521–4528 (2017).
pubmed: 28849115
pmcid: 5647099
doi: 10.3892/mmr.2017.7203
Barrantes, A., Rejas, M. T., Benitez, M. J. & Jiménez, J. S. Interaction between Alzheimer’s Aβ1–42 peptide and DNA detected by surface plasmon resonance. J. Alzheimers Dis. 12, 345–355 (2007).
pubmed: 18198421
doi: 10.3233/JAD-2007-12408
Szybińska, A. & Leśniak, W. P53 dysfunction in neurodegenerative diseases - the cause or Effect of pathological changes? Aging Dis. 8, 506–518. https://doi.org/10.14336/ad.2016.1120 (2017).
doi: 10.14336/ad.2016.1120
pubmed: 28840063
pmcid: 5524811
Jiang, L. et al. Ferroptosis as a p53-mediated activity during tumour suppression. Nature. 520, 57–62 (2015).
pubmed: 25799988
pmcid: 4455927
doi: 10.1038/nature14344
Huang, L. et al. Intracellular amyloid toxicity induces oxytosis/ferroptosis regulated cell death. Cell Death Dis. 11, 828 (2020).
pubmed: 33024077
pmcid: 7538552
doi: 10.1038/s41419-020-03020-9
Zhang, Y. et al. Ferredoxin reductase is critical for p53-dependent tumor suppression via iron regulatory protein 2. Genes Dev. 31, 1243–1256 (2017).
pubmed: 28747430
pmcid: 5558926
doi: 10.1101/gad.299388.117
Zhang, Z. et al. The BRD7-P53-SLC25A28 axis regulates ferroptosis in hepatic stellate cells. Redox Biol. 36, 101619 (2020).
pubmed: 32863216
pmcid: 7330619
doi: 10.1016/j.redox.2020.101619
Xu, R., Wang, W. & Zhang, W. Ferroptosis and the bidirectional regulatory factor p53. Cell. Death Discovery. 9, 197. https://doi.org/10.1038/s41420-023-01517-8 (2023).
doi: 10.1038/s41420-023-01517-8
pubmed: 37386007
pmcid: 10310766
Ou, Y., Wang, S-J., Li, D., Chu, B. & Gu, W. Activation of SAT1 engages polyamine metabolism with p53-mediated ferroptotic responses. Proc. Natl. Acad. Sci. 113, E6806–E6812 (2016).
pubmed: 27698118
pmcid: 5098629
doi: 10.1073/pnas.1607152113
Ou, M. et al. Role and mechanism of ferroptosis in neurological diseases. Mol. Metabolism. 61, 101502 (2022).
doi: 10.1016/j.molmet.2022.101502